-
News | 2020.05.14
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
The LuLISA (Luciferase-Linked ImmunoSorbent Assay) research project aims developing high throughput serological tests for epidemiological studies at local, regional or nation scales. In a recent scientific publication, concerning the detection and dosing of IgE specific to several allergens in patients’ blood samples, the use of LuLISA proves to be a vastly improved detection method in...
-
Article | 2020.10.14
Covid-19: vaccine against SARS-CoV-2 infection, using the measles vector
Phase I testing in humans for the Institut Pasteur's SARS-CoV-2 vaccine candidate using the measles vector was lauchned in August 2020 in France and Belgium. Following the intermediate results of the Phase I clinical trial, the Institut Pasteur is stopping (January, 2021) development of the vaccine candidate based on the measles platform.
-
News | 2022.07.11
A snapshot of 2021's highlights
Following the release of the 2021 edition of the Institut Pasteur's Annual Report, here are some of the year's highlights. Twelve eventful months interspersed with highlightsmajor scientific breakthroughs and key events for the institute in all fields including COVID-19, cancer, neuroscience, genetics, vaccinology and antibiotic resistance.
-
Report | 2020.04.03
Coronavirus SARS-CoV-2: A look back at three months of mobilisation against an emerging disease (COVID-19)
On December 31, 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. It was the official beginning of an epidemic that would rapidly become worldwide. In January, a task force was put in place at the Institut Pasteur and research projects were quickly launched. Here is a look back at three...
-
Article | 2020.06.22
Investigation of the first cases of coronavirus (COVID-19) infections and their contacts in Antananarivo, Madagascar
Aim: This study aims to understand the epidemiologic, clinical, virologic and immunologic characteristics of first infected cases, their evolution and household transmission. It is intended to follow confirmed infected cases and their household members. It will be conducted with clinicians from three hospital centers of Antananarivo.
-
Article | 2020.07.07
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
-
Article | 2020.07.07
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
-
Article | 2020.07.07
COVID-19: mathematical model indicates that between 3% and 7% of French people have been infected
COVID-19: mathematical model indicates that between 3% and 7% of French people have been infected
-
News | 2022.02.23
What is long COVID ?
In May 2020, while the first wave of the COVID-19 outbreak was coming to an end in France, initial reports emerged of patients with some persistent symptoms several weeks or months post-infection. This phenomenon, now referred to as "long COVID" (or post-COVID-19 syndrome) affects over 20% of patients after 5 weeks and over 10% of patients after 3 months. Serious or severe forms of initial SARS-...
-
News | 2024.12.09
Lessons learned from the COVID-19 crisis: improving protection through early response, rapid tracking and impact monitoring
Scientific experts from 13 Western European countries have recently completed a review of key lessons learned from the way the COVID-19 pandemic was handled. Two key findings have emerged. Firstly, death rates were lower in countries that took measures early. Secondly, the need for a surveillance system capable of quickly tracking the community spread of a virus and its impact on hospitals was...
